文献速递角膜与眼表疾病白内障与屈光手术

加速交联联合准分子激光原位角膜磨镶术治疗近视患者:系统综述与荟萃分析

Combined Accelerated Crosslinking With Laser In Situ Keratomileusis (LASIK) for Myopic Patients: A Systematic Review and Meta-Analysis.
PubMed 文献 · Am J Ophthalmol · 2025-05-31

该系统综述与荟萃分析纳入15项研究共1647眼(LASIK 836眼,LASIK Xtra 811眼),比较LASIK与同时行LASIK和加速交联(LASIK Xtra)矫正近视的效果。结果显示LASIK在术后裸眼远视力(UDVA)上优于LASIK Xtra(1个月MD -0.03,P=.007;≥6个月MD -0.01,P=.02),但证据确定性为低至极低,结论需谨慎解读并通过长期研究进一步确认。

要点

  • LASIK组术后UDVA优于LASIK Xtra组,1个月MD -0.03(P=.007),≥6个月MD -0.01(P=.02)。
  • 矫正远视力、等效球镜、安全性、有效性、可预测性和稳定性方面两组无显著差异。
  • Ectasia风险组行LASIK Xtra术后CDVA丢失风险更高(OR=0.20,95%CI 0.04-0.97,P=.05)。

核心结论

  • 当前证据提示LASIK在UDVA上较LASIK Xtra有统计学显著优势,尤其在LASIK Xtra采用30 mW/cm²照射90秒(2.7 J/cm²)方案时;但鉴于证据确定性为低至极低,这些发现需谨慎解读并通过长期研究进一步确认。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、EMBASE、Web of Science、Cochrane Library和中国知网至2024年10月1日,纳入比较LASIK与LASIK Xtra矫正近视的研究。
  • 共纳入15项研究、1647眼,其中LASIK 836眼,LASIK Xtra 811眼。

主要发现

  • LASIK组术后UDVA优于LASIK Xtra组:1个月MD -0.03(8项研究,n=750眼;95%CI -0.04至-0.01,P=.007);长期(≥6个月)MD -0.01(7项研究,n=672眼;95%CI -0.02至0.00,P=.02)。
  • 矫正远视力(6项研究,n=530眼;MD=0.00,95%CI -0.01至0.00,P=.32)、等效球镜(14项研究,n=1639眼;MD=0.03,95%CI -0.03至0.08,P=.40)两组无显著差异。
  • 安全性(8项研究,n=779眼;OR=0.70,95%CI 0.39至1.26,P=.23)、有效性(11项研究,n=921眼;OR=0.75,95%CI 0.54至1.05,P=.10)、可预测性(11项研究,n=971眼;OR=1.03,95%CI 0.72至1.47,P=.86)、稳定性(3项研究,n=90眼;OR=0.70,95%CI 0.21至2.28,P=.55)两组均无显著差异。
  • 亚组分析显示Ectasia风险组行LASIK Xtra术后CDVA丢失风险更高(OR=0.20,95%CI 0.04至0.97,P=.05)。
  • LASIK Xtra采用30 mW/cm²照射90秒(2.7 J/cm²)方案可能导致UDVA较LASIK更差(MD=-0.01,95%CI -0.03至-0.001,P=.05)。

临床怎么用

  • 作者认为当前证据提示LASIK在UDVA上较LASIK Xtra有统计学显著优势,尤其在LASIK Xtra采用30 mW/cm²照射90秒(2.7 J/cm²)方案时,但鉴于证据确定性低至极低,需谨慎解读并通过长期研究进一步确认。

局限性

  • 各结局的证据确定性范围为低至极低。
  • 作者指出鉴于证据确定性低至极低,这些发现需谨慎解读并通过长期研究进一步确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare laser in situ keratomileusis (LASIK) and Simultaneous LASIK and accelerated Crosslinking (LASIK Xtra) for myopia correction. DESIGN: Systematic review and meta-analysis. METHODS: A search of PubMed, EMBASE, Web of Science, the Cochrane Library, and China National Knowledge Internet was conducted up to October 1, 2024 to identify studies comparing LASIK and LASIK Xtra for myopia correction. The outcome of visual acuity and refraction, safety, efficiency, predictability, stability, postoperative corneal thickness and endothelial cell count were measure. RESULTS: A total of 1,647 eyes (836 LASIK, 811 LASIK Xtra) from 15 studies were included. LASIK demonstrated superior postoperative uncorrected distance visual acuity (UDVA) compared to LASIK Xtra, with a mean difference (MD) of -0.03 (8 studies, n = 750 eyes; 95% CI: -0.04 to -0.01, P = .007) at 1 month and (7 studies, n = 672 eyes; MD= -0.01 95% CI: -0.02 to 0.00, P = .02) for long-term results (≥6 months). No significant differences were found in corrected distance visual acuity (CDVA; 6 studies, n = 530 eyes; MD = 0.00, 95% CI: -0.01, 0.00, P = .32), spherical equivalent (14 studies, n = 1639 eyes; MD = 0.03, 95% CI: -0.03, 0.08; P = .40), safety (8 studies, n = 779 eyes; odds ratios [OR]= 0.70; 95% CI: 0.39, 1.26; P = .23), efficiency (11 studies, n = 921 eyes; OR = 0.75, 95% CI: 0.54, 1.05, P = .10), predictability (11 studies, n = 971 eyes; OR= 1.03, 95% CI: 0.72, 1.47, P = .86), stability (3 studies, n = 90 eyes; OR = 0.70, 95% CI: 0.21, 2.28, P = .55). Subgroup analysis indicated a higher risk of postoperative CDVA loss in the Ectasia Risk Group undergoing LASIK-Xtra (OR= 0.20, 95% CI: 0.04 to 0.97, P = .05). The 30 mW/cm² for 90 seconds (2.7 J/cm²) irradiation protocol in LASIK Xtra may resulted in worse UDVA compared to LASIK (MD= -0.01, 95% CI: -0.03 to -0.001, P = .05). The certainty of evidence for the outcomes ranged from "low to very low". CONCLUSIONS: Current evidence suggests that LASIK offers a statistically significant advantage in UDVA compared to LASIK Xtra, especially when LASIK Xtra irradiation protocol of 30 mW/cm² for 90 seconds (2.7 J/cm²) is applied. However, given the low to very low certainty of evidence, these findings require cautious interpretation and further confirmation through long-term studies.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Tian H, Chang L, Yang M, et al. Combined Accelerated Crosslinking With Laser In Situ Keratomileusis (LASIK) for Myopic Patients: A Systematic Review and Meta-Analysis. Am J Ophthalmol. 2025. PMID: 40456396. doi:10.1016/j.ajo.2025.05.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。